Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ZBH

How Is Zimmer Biomet Holdings' Stock Performance Compared to Other Medical Device Stocks?

Zimmer Biomet Holdings has significantly underperformed other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.

MarketBeat

3 Healthcare Technology Companies Revolutionizing Patient Care

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Wall Street Bullish or Bearish on Zimmer Biomet Stock?

While Zimmer Biomet has lagged behind the broader market over the past year, analysts continue to hold a moderately positive view on the stock's prospects.

Barchart

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

StockNews.com

3 Medical Devices Stocks Poised for Solid Growth

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more….

StockNews.com

Here's What to Expect From Zimmer Biomet Holdings' Next Earnings Report

Zimmer Biomet Holdings is expected to release its third-quarter earnings later this month, and analysts expect a single-digit earnings growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is STERIS Stock Underperforming the S&P 500?

STERIS has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish about the stock’s potential.

Barchart

Zimmer Biomet Stock: Is ZBH Underperforming the Healthcare Sector?

Zimmer Biomet has underperformed the healthcare sector over the past year, yet analysts remain moderately bullish about the stock’s prospects.

Barchart

3 High-Growth MedTech Stocks to Buy

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

StockNews.com

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Despite Zimmer Biomet underperforming the broader market over the past year, analysts remain moderately bullish on the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Zimmer Biomet’s Report

Zimmer Biomet will release its second-quarter earnings next month, and analysts anticipate a single-digit profit growth.

Barchart

3 Oversold Stocks With Buy Signals

Investing in oversold stocks can be a potentially profitable strategy for investors who are willing to take calculated risks and have a long-term perspective. Amid this backdrop, investors could consider buying fundamentally strong oversold stocks Comcast (CMCSA), Northrop Grumman (NOC), and Zimmer Biomet Holdings (ZBH) with an RSI below 30.…

StockNews.com

Analyzing Buy or Hold Options for 3 Medical Stocks

The medical industry is thriving due to rising demand for healthcare products and services, fueling significant returns. Given the solid long-term prospects of the industry, let’s analyze fundamentally sound medical stocks McKesson (MCK), Zimmer Biomet (ZBH) and Fresenius SE (FSNUY).

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Should you Buy or Sell These 3 Medical Stocks?

Thanks to the rising awareness of the benefits of digital health services and technological advancements, the medical industry is poised for remarkable growth. While the industry outlook may seem promising, should one buy or sell Medtronic (MDT), Zimmer Biomet (ZBH), and Merit Medical (MMSI)? Read more to find out.

Investors Business Daily

Dow Jones Futures Fall: Market Rally Resilient After Fed Surprise; Tesla Ends Record Run

The market rally held up, for now, amid a Fed forecast of two more rate hikes. Tesla ended a big win streak. Medical product firms flashed buy signals.

StockNews.com

3 Wide-Moat Stocks to Buy in June

The stock market has been witnessing wild swings lately amid growing concerns over the Fed’s aggressive interest rate hikes to combat the multi-decade high inflation, supply bottlenecks, ongoing geopolitical crisis, and possibility of a recession. However, wide-moat stocks have competitive advantages and tend to outperform their peers in the long…

StockNews.com

Are Medical Device Stocks Good Investments During a Recession?

The stock market has witnessed a massive sell-off lately on concerns over the Fed’s aggressive interest rate hikes to fight the decade-high inflation. Many analysts expect the economy to slip into recession due to the Fed’s monetary policy tightening. Since the medical device industry is known to be one of…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyst Ratings for Zimmer Biomet Holdings

Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings:

Benzinga

Zimmer Biomet Raises, Tightens FY22 Outlook after Q1 Earnings Surpass Estimates

Zimmer Biomet Holdings Inc's (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, which came in above the consensus of $1.41 and $1.55 a year ago. "We are encouraged by the better than expected results…

Benzinga

Zimmer Biomet: Q1 Earnings Insights

Zimmer Biomet Holdings (NYSE:ZBH) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

StockNews.com

Abbott Laboratories vs. Zimmer Biomet Holdings: Which Medical Device Stock is a Better Buy?

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

Benzinga

Friday Is Your Last Chance To Buy Zimmer Biomet Holdings Before The Dividend Payout

Friday marks the last chance for investors to receive the next dividend payout from Zimmer Biomet Holdings (NYSE:ZBH).

StockNews.com

Should You Scoop Up Shares of Zimmer Biomet Holdings on the Dip?

The shares of healthcare products and solutions provider Zimmer Biomet (ZBH) plunged in price after the company posted a dismal fourth-quarter earnings report. The company cited pandemic-induced challenges as having hampered its performance, while also anticipating these challenges will persist this year. So, will ZBH’s stock be able to gain…

Benzinga

Analyst Ratings For Zimmer Biomet Holdings

Over the past 3 months, 10 analysts have published their opinion on Zimmer Biomet Holdings (NYSE:ZBH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

People

Jerome Powell

2,773 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.